Proteomics of Severe Traumatic Brain Injury: A Feasibility Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00522496 |
Recruitment Status
: Unknown
Verified February 2009 by University of Calgary.
Recruitment status was: Recruiting
First Posted
: August 29, 2007
Last Update Posted
: February 24, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to:
- Determine the temporal course of matrix metalloproteinase (MMP) expression in patients wiht severe traumatic brain injury
- Determine the temporal course of the expression of MMP-related inflammatory mediators of secondary injury in patients with severe traumatic brain injury
- Describe the association of physiological changes and standard microdialysis analyte measures (lactate, pyruvate, lactate/pyruvate ratio, and glucose) to MMP and neuroinflammatory marker concentrations.
Condition or disease |
---|
Brain Injuries, Traumatic |
Study Type : | Observational |
Estimated Enrollment : | 8 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Proteomics of Severe Traumatic Brain Injury: A Feasibility Study |
Study Start Date : | July 2007 |
Estimated Study Completion Date : | August 2009 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patient is 18 years of age or older
- Patient has GCS less than 9
- Patient requires intracranial pressure monitoring
- Patient life expectancy greater than 72 hours
Exclusion Criteria:
- Patient's TBI is greater than 24 hours old
- Patient is less than 18 years of age
- Patient does not require intracranial pressure monitoring
- Patient has life expectancy less than 72 hours
- Patient has GCS greater or equal to 9
- Patient is currently enrolled in another study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00522496
Contact: David A Zygun, MD | 403-944-1691 | dzygun@ucalgary.ca |
Canada, Alberta | |
Foothills Medical Centre | Recruiting |
Calgary, Alberta, Canada, T2N 2T9 | |
Contact: David A Zygun, MD 403-944-1691 dzygun@ucalgary.ca | |
Principal Investigator: David A Zygun, MD | |
Sub-Investigator: John Hurlbert, MD | |
Sub-Investigator: Ian Parney, MD | |
Sub-Investigator: Walter Hader, MD | |
Sub-Investigator: Clare Gallagher, MD | |
Sub-Investigator: Wee Yong, P.hD | |
Sub-Investigator: Christopher Doig, MD | |
Sub-Investigator: Paul Kubes, MD | |
Sub-Investigator: Andreas Kramer, MD |
Principal Investigator: | Zygun A David, MD | University of Calgary |
Responsible Party: | David Zygun Principal Investigator, University of Calgary |
ClinicalTrials.gov Identifier: | NCT00522496 History of Changes |
Other Study ID Numbers: |
20216 |
First Posted: | August 29, 2007 Key Record Dates |
Last Update Posted: | February 24, 2009 |
Last Verified: | February 2009 |
Keywords provided by University of Calgary:
Craniocerebral trauma matrix metalloproteinase microdialysis |
Additional relevant MeSH terms:
Wounds and Injuries Brain Injuries Brain Injuries, Traumatic Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System |